Oddo BHF raised target for Novo Nordisk stock from DKK 221 to DKK 305
π Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305 on October 20, 2026.
π The stock traded at EUR 34.88 on October 26, 2026, down 0.34% versus the Xetra close and 34.75% below the 52-week high.
π° Novo Nordisk repurchased 39.07 million B shares for DKK 10.88 billion under its buyback program by October 16, 2026.
π Diabetes and obesity treatments account for 93.7% of net sales, while rare-disease treatments comprise 6.3%.
π The company is scheduled to release third-quarter results on November 3, 2026.
π Novo Nordisk's year-to-date performance was minus 20.02% in Danish kroner through October 23, 2026.
π’ The company employs 66,700 people and maintains a market capitalization of DKK 1,150.6 billion.
Bullish Signals
- Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305 on October 20, 2026.
- Novo Nordisk executed a significant share buyback program, repurchasing 39.07 million B shares for DKK 10.88 billion by October 16, 2026.
Risk Factors
- Novo Nordisk stock traded at EUR 34.88 on October 26, 2026, which is 34.75% below its 52-week high of EUR 53.46.
- The company's year-to-date performance was negative at minus 20.02% in Danish kroner through October 23, 2026.
Full Analysis
Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305 on October 20, 2026, while maintaining a Neutral rating. The Danish pharmaceutical giant's stock was trading at EUR 34.88 on October 26, 2026, representing a modest decline of 0.34% against the previous Xetra close and sitting approximately 34.75% below its 52-week high.
Novo Nordisk has been actively executing its share buyback program, having repurchased 39.07 million B shares for DKK 10.88 billion by October 16, 2026. This capital return initiative began on February 4, 2026, and the company's market capitalization stood at DKK 1,150.6 billion as of late October.
The company's business remains heavily focused on its core therapeutic areas, with diabetes and obesity treatments accounting for 93.7% of net sales and rare-disease treatments making up the remaining 6.3%. Investors are now awaiting the third-quarter results scheduled for release on November 3, 2026, which will serve as a key test for the business following recent analyst revisions and buyback activity.
Despite the positive analyst target adjustment, Novo Nordisk's year-to-date performance in Danish kroner has been negative at minus 20.02% through October 23, 2026. The stock continues to trade within a wide range between EUR 30.40 and EUR 53.46, reflecting ongoing market volatility around the ticker.